Keith Howard Email & Phone Number

aVaxziPen is an innovative pharmaceutical company developing needle-free, solid dose, injectable products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare.The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organisations.

Oxford, United Kingdom

Head of Manufacturing. Responsible for leading Research and Development; providing oversight of design, construction, manufacture, and evaluation of vaccine candidates. Responsible for the management of the manufacture of clinical trial material and for the operation and compliance of the Vaccitech's lab facilities.

Liverpool, United Kingdom

Head of Department, Manufacturing Science & Technology; supporting the manufacture and process development activities of the Medimmune live attenuated seasonal influenza vaccine, FluMist/Fluenz. MSAT develops and evaluates candidate vaccine seed viruses, develops process improvements, and establishes and improves a range of molecular biology-, virology-, and immunology-based analytical assays.

Orth An Der Donau, Austria

Head of department. Management of assay development to support the manufacture and release of licensed vaccines against tick-borne encephalitis and Meningitis C. Additional small scale upstream model activities to support TBEV vaccine manufacturing and process development.

Orth An Der Donau, Austria

Head of Virology R&D. Management of non-clinical research on prophylactic inactivated whole virus vaccines to seasonal influenza, pandemic and avian influenza, Tick-borne encephalitis virus, SARS corona virus, Ross River virus, chikungunya virus and other emerging viruses. Additionally providing support to clinical, quality, manufacturing, regulatory and marketing functions from non-clinical research through to licensure and life cycle management activities.

Oxford, United Kingdom

Management of R&D Group constructing therapeutic vaccines to cancer and chronic infections (melanoma, hepatitis B, HIV) based on recombinant plasmids, MVA, fowlpox, HSV, and adenovirus vectors. Established and managed Virology Group, Process Development Group and analytical support.

Responsible for the design and construction of a highly disabled HSV1 vector system based on the DISC-HSV vaccine. Project manager for the design and construction of gene therapy vectors for lysosomal storage diseases (Gaucher's) and Parkinson's Disease. Managed the process development team during the establishment of a scaleable purification process for HSV1 vectors.

Bachelor Of Science (Bsc), Biological Sciences

Education record